| 1 | 113 | Drug Product Stability pharm. | telce | 23.09.2009 | 20:22 |
| 1 | 96 | Priorities Commission med. | telce | 10.09.2009 | 19:03 |
| 1 | 121 | German AO | telce | 30.08.2009 | 12:08 |
| 1 | 110 | Pelvic Courses med. | telce | 30.08.2009 | 10:38 |
| 1 | 87 | BOARD CERTIFICATE med. | telce | 26.08.2009 | 22:54 |
| 50 | Joint Council of Research med. | telce | 24.08.2009 | 9:04 | |
| 4 | 131 | Development Therapeutics med. | telce | 23.08.2009 | 22:56 |
| 1 | 634 | Prof. Dr.Dr. h.c. med. | telce | 23.08.2009 | 21:59 |
| 7 | 168 | alleged as opposed to confirmed pharm. | telce | 21.08.2009 | 21:56 |
| 2 | 95 | considered censored pharm. | telce | 6.04.2009 | 1:16 |
| 2 | 104 | sign informed consent pharm. | telce | 5.04.2009 | 0:35 |
| 8 | 437 | discontinue - withdraw pharm. | telce | 4.04.2009 | 23:35 |
| 3 | 102 | monitoring boundary pharm. | telce | 2.04.2009 | 14:16 |
| 24 | 626 | patient-death pharm. | telce | 2.04.2009 | 0:47 |
| 2 | 99 | key personnel pharm. | telce | 2.04.2009 | 0:29 |
| 4 | 382 | manageable toxicity profile med. | telce | 1.04.2009 | 22:51 |
| 1 | 318 | O'Brien-Fleming-type alpha spending function pharm. | telce | 31.03.2009 | 0:28 |
| 4 | 910 | ITT analysis pharm. | telce | 30.03.2009 | 23:58 |
| 151 | TARGET pharm. | telce | 29.03.2009 | 23:18 | |
| 1 | 70 | Assessment Randomized Protocol Trial pharm. | telce | 27.03.2009 | 11:39 |
| 2 | 85 | state and country | telce | 27.03.2009 | 9:55 |
| 1 | 83 | extrahepatic spread med. | telce | 26.03.2009 | 20:16 |
| 1 | 90 | Barcelona-Clinic Liver Cancer med. | telce | 26.03.2009 | 0:11 |
| 1 | 80 | subject to license fee pharm. | telce | 25.03.2009 | 23:29 |
| 1 | 79 | Landmark study med. | telce | 21.03.2009 | 23:08 |
| 2 | 125 | coping with urbanization med. | telce | 21.03.2009 | 18:35 |
| 5 | 159 | Помогите, пожалуйста! pharm. | telce | 11.03.2009 | 1:05 |
| 1 | 70 | Population-PK cohort pharm. | telce | 10.03.2009 | 20:32 |
| 1 | 412 | Intensive-PK cohort pharm. | telce | 9.03.2009 | 20:02 |
| 2 | 343 | intensive pharmacokinetic sampling scheme pharm. | telce | 9.03.2009 | 1:16 |
| 2 | 1057 | standard-of-care (SOC) guidelines. pharm. | telce | 9.03.2009 | 0:23 |